WK
Highly rated in
29
conditions
Highly rated in
29
conditions
Check Dr. William H. Kreisle's experience treating your condition:
About Dr. William H. Kreisle

William Kreisle is a Hematologist Oncology specialist and an Oncologist in Boise, Idaho. Kreisle has been practicing medicine for over 37 years and is highly rated in 29 conditions, according to our data. His top areas of expertise are Relapsed Refractory Multiple Myeloma RRMM, Multiple Myeloma, Childhood Acute Myeloid Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in Idaho. Kreisle is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 2 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. William H. Kreisle it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. William H. Kreisle accepts the following insurance:

  •  Ambetter
  •  PacificSource
  •  Montana Health Cooperative
  •  Moda Health

Call to see if your plan is accepted.
Locations
100 E Idaho St, Suite 200, Boise, ID 83712
Background & Education
Graduate Institution
Baylor College Of Medicine, 1985
Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in ID
Hospital Affiliations
St Lukes Magic Valley Medical Center
St Lukes Elmore Medical Center
St Lukes Nampa Medical Center
St Lukes Boise Medical Center
St Lukes McCall Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


2 Clinical Trials

Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
View 1 Less Clinical Trial -

2 Total Publications

Midostaurin and cyclosporine drug interaction: A case report.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors